Conference Coverage

ILC: New single daily pill eradicates hepatitis C


 

AT THE INTERNATIONAL LIVER CONGRESS 2015

References

The C-EDGE trial was sponsored by Merck, which is developing the drugs used in the study. Dr. Zeuzem has been a consultant for and speaker on behalf of Merck and for AbbVie, Bristol-Myers Squibb, Gilead, and Janssen. Dr. Reddy has been a consultant to and received research support from Merck and Bristol-Myers Squibb, AbbVie, Janssen, and Gilead, Dr. Jensen had no disclosures.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

Behavioral symptoms in dementia need a global touch
MDedge Family Medicine
Metabolic monitoring suboptimal for dementia patients taking antipsychotics
MDedge Family Medicine
Blocking breakdown of arginine may prevent AD
MDedge Family Medicine
Memantine plus cholinesterase inhibitor improves behavioral symptoms in Alzheimer’s
MDedge Family Medicine
Study aims to bolster argument for reimbursing amyloid imaging
MDedge Family Medicine
Elderly suicidality tied to disability, isolation
MDedge Family Medicine
Novel oral anticoagulants best warfarin for AF in heart failure
MDedge Family Medicine
VIDEO: Expert picks top studies in Alzheimer’s, migraine, and stroke at AAN
MDedge Family Medicine
ACCP and CTS issue joint guideline on COPD exacerbations
MDedge Family Medicine
AAN: Cleveland mobile stroke unit reduces time to thrombolysis
MDedge Family Medicine